Dipeptidyl peptidase-4 inhibitors in progressive kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 1, 2015, Pages 67-73

  Makino, Yuichi ^a   Fujita, Yukihiro ^a   Haneda, Masakazu ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Diabetic nephropathy; DPP 4 inhibitor; GLP 1; Incretin

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GEMIGLIPTIN; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TELMISARTAN; VILDAGLIPTIN; GASTRIC INHIBITORY POLYPEPTIDE;

CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FUNCTION; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; REVIEW; ANIMAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ENZYMOLOGY; KIDNEY; METABOLISM;

ANIMALS; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; KIDNEY;

EID: 84918827374     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000080     Document Type: Review

References (60)

1. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34:795-808.
2. Vejakama P, Thakkinstian A, Lertrattananon D, et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012; 55:566-578.
3. Rossing P, de Zeeuw D. Need for better diabetes treatment for improved renal outcome. Kidney Int Suppl 2011; 120:S28-S32.
4. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in pa tients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
6. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517-523.
7. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010; 90:131-140.
8. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705.
9. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27 (Suppl. 3):57-64.
10. Holst JJ. Th e physiology of glucagon-like peptide 1. Physiol Rev 2007; 87:1409-1439.
11. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137:2968-2978.
12. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinic al trials. Diabetes Obes Metab 2013; 15:737-749.
13. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in h ealthy humans. Am J Physiol 1997; 273:E981-E988.
14. Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol 2012; 74:437-444.
15. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187-215.
16. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011; 27:547-558.
17. Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. De s-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007; 292:R897-R901.
18. Grouzmann E, Bigliardi P, Appenzeller M, et al. Substanc e P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers. Biol Chem 2011; 392:217-221.
19. Mentlein R, Dahms P, Grandt D, Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993; 49:133-144.
20. Shioda T, Kato H, Ohnishi Y, et al. Anti-HIV-1 and chemotactic activities of human stromal cell-d erived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 1998; 95:6331-6336.
21. Marchetti C,Di Carlo A,Facchiano F,et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV, Diabetologia, 2012; 55: 236-244.
22. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diur etic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011; 301:F355-F363.
23. Fujita H, Morii T, Fujishima H, et al. The protective roles of G LP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014; 85:579-589.
24. Kö rnerM, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48:736-743.
25. Schlatter P, Beglinger C, Drew e J, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007; 141:120-128.
26. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 rec eptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE (-/-) mice. Endocrinology 2013; 154:127-139.
27. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 2002; 434:163-167.
28. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89:3055-3061.
29. Skov J, Dejgaard A, Frokiaer J, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemod ynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013; 98:E664-E671.
30. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21:1125-1135.
31. Liu Q, Adams L, Broyde A, et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfun ction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010; 9:32. doi: 10.1186/1475-2840-9-32.
32. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19:567-575.
33. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endotheli al cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther 2013; 27:371-380.
34. Ishibashi Y, Nishino Y, Matsui T, et al. Glucagon-like peptide-1 suppresses advanced glycatio n end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011; 60:1271-1277.
35. Mima A, Hiraoka-Yamomoto J , Li Q, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61:2967-2979.
36. Rieg T, Gerasimova M, Murray F, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 2012; 303:F963-F971.
37. Mentlein R. Cell-surface peptidases. Int Rev Cytol 2004; 235:165-213.
38. Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 2009; 30:229-240.
39. Hocher B, Sharkovska Y, Mark M, et al. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol 2013; 167:87-93.
40. Jungraithmayr W, De Meester I, Matheeussen V, et al. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg 2012; 41:1166-1173.
41. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003; 82:53-73.
42. Park CW,Kim HW,Ko SH,et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol, 2007;18: 1227-1238.
43. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of typ e 1 diabetes. Diabetologia 2011; 54:965-978.
44. Yang J, Campitelli J, Hu G, et al. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin . Life Sci 2007; 81:272-279.
45. Stefanovic V, Ardaillou N, Vlahovic P, et al. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 1993; 80:465-470.
46. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012; 340:248-255.
47. Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011:162092; doi: 10.1155/2011/162092. [Epub ahead of print]
48. Marques C, Mega C, Gonc alves A, et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic a nimals. Mediators Inflamm 2014; 2014:538737; doi: 10.1155/2014/538737. [Epub ahead of print]
49. Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36:119-130.
50. Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition amel iorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014; 63:2120-2131.
51. Kodera R, Shikata K, Takatsu ka T, et al. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 2014; 443:828-833.
52. Joo KW, Kim S, Ahn SY, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol 2013; 14:98. doi: 10.1186/1471-2369-14-98.
53. Min HS, Kim JE, Lee MH, et al. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest 2014; 94:598-607.
54. Li J, Guan M, Li C, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in apolipoprotein E knockout mice. Int J Mol Sci 2014; 15:11416-11434.
55. Nistala R, Habibi J, Lastra G, et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology 2014; 155:2266-2276.
56. Hattori S. Sitag liptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011; 58:69-73.
57. Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig 2014; 5:313-319.
58. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326.
59. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diab etes Care 2013; 36:3460-3468.
60. Fujita H, Taniai H, Murayama H, et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via upregulation of SDF-1a in type 2 diabetic patients with incipient nephropathy. Endocr J 2014; 61:159-166.